Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) is pleased to announce the first procedures using the Company’s products following CE mark of the Vision-MR Ablation Catheter have been performed at the Heart Center Dresden.

Imricor Medical Systems, Inc. (ASX:IMR) today announces that it has received CE mark approval for its Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode. This follows earlier CE mark approval for Imricor to place its Advantage-MR EP Recorder/Stimulator System on the market in the European Union. Imricor is the first and only company to offer cardiac ablation in the MRI environment.

Imricor Medical Systems, Inc. (ASX:IMR), a leading developer of innovative MRI-compatible medical devices, announced today Nick Twohy has joined the company’s executive team as the Director of Marketing.

Imricor announced today that they have signed a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit an MRI ablation center for treating cardiac arrhythmias.

Imricor announced today that it signed its first commercialization contract in the Netherlands with the Amsterdam University Medical Center, location VUmc, for the Advantage-MR™ EP Recorder/Stimulator System. With this agreement, Amsterdam UMC will become the first Dutch site to install the Advantage-MR system and perform real-time MRI-guided cardiac ablations, placing them at the forefront of clinical adoption for interventional cardiac magnetic resonance (iCMR) electrophysiology procedures.

Imricor announced today that it signed its first commercialization contract for the Advantage-MR EP Recorder/Stimulator System and supporting Vision-MR devices1 with the Heart Center Dresden in Germany. This agreement places the Heart Center Dresden at the forefront of clinical advancement for MRI-guided cardiac ablations and establishes the hospital as a world leader in the growing field of interventional cardiac magnetic resonance (iCMR).